All In Biotech

NDA 203340 · Azurity

Nymalize

Nimodipine · Oral · Dihydropyridine Calcium Channel Blocker

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

May 10, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

40

5 Phase 3, 3 recruiting

FAERS reports

1,122

980 serious, 115 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 30, 2024.

NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). NYMALIZE is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). ( 1 )

Mechanism: Nimodipine is a dihydropyridine calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood-brain barrier; concentrations of nimodipine as high as 12.5 ng/mL have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • NYMALIZE · NIMODIPINE 3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
  • NYMALIZE · NIMODIPINE 6MG/ML · SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nimodipine" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective89
  • off label use72
  • hypotension59
  • subarachnoid haemorrhage43
  • toxicity to various agents34
  • diarrhoea33
  • dizziness33
  • headache33
  • drug interaction32
  • renal failure31
  • reversible cerebral vasoconstriction syndrome31
  • condition aggravated29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
20054
200613
200715
200828
200929
201041
201140
201240
201336
201454
201555
201643
201747
201879
201968
202094
202181
202265
202385
202469
202578
202643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 444 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.